within Pharmacolibrary.Drugs.ATC.N;

model N02AE01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 57 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.43,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Buprenorphine is a semi-synthetic opioid used primarily for pain management and in the treatment of opioid use disorder. It acts as a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Buprenorphine is approved for medical use in many countries and is commonly used in both pain and addiction treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following a single sublingual tablet administration.</p><h4>References</h4><ol><li><p>Elkader, A, &amp; Sproule, B (2005). Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. <i>Clinical pharmacokinetics</i> 44(7) 661–680. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544070-00001&quot;>10.2165/00003088-200544070-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15966752/&quot;>https://pubmed.ncbi.nlm.nih.gov/15966752</a></p></li><li><p>Lim, SCB, et al., &amp; Krishnarajah, J (2019). The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. <i>Pain medicine (Malden, Mass.)</i> 20(1) 143–152. DOI:<a href=&quot;https://doi.org/10.1093/pm/pnx321&quot;>10.1093/pm/pnx321</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29309700/&quot;>https://pubmed.ncbi.nlm.nih.gov/29309700</a></p></li><li><p>Gu, M, et al., &amp; Zhu, X (2023). Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. <i>Frontiers in pharmacology</i> 14 1089862–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1089862&quot;>10.3389/fphar.2023.1089862</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744255/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744255</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02AE01;
